Expertise in
6
conditions

Dr. James Maynard

Sleep Medicine
Cti Clinical Research Center
1775 W Lexington Ste 200, 
Cincinnati, OH 
Expertise in
6
conditions
Cti Clinical Research Center
1775 W Lexington Ste 200, 
Cincinnati, OH 

Overview

James Maynard is a Sleep Medicine provider in Cincinnati, Ohio. Dr. Maynard is highly rated in 6 conditions, according to our data. His top areas of expertise are Familial Hemiplegic Migraine, Migraine with Brainstem Aura, Obstructive Sleep Apnea, and Excessive Daytime Sleepiness.

His clinical research consists of co-authoring 6 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Sleep Medicine

Licenses

Psychiatry & Neurology in KY

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Cti Clinical Research Center
1775 W Lexington Ste 200, Cincinnati, OH 45212

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension
Enrollment Status: Active_not_recruiting
Publish Date: January 14, 2026
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
A Master Protocol to Investigate the Efficacy and Safety of Tirzepatide Once Weekly in Participants Who Have Obstructive Sleep Apnea and Obesity: A Randomized, Double-Blind, Placebo-Controlled Trial
Enrollment Status: Completed
Publish Date: April 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy
A Pilot Proof of Concept Pharmacokinetic/Pharmacodynamic Study of BXQ-350 in Cancer Patients Exposed to Oxaliplatin and/or Taxane-Based Chemotherapy
Enrollment Status: Completed
Publish Date: January 27, 2025
Intervention Type: Other, Drug
Study Phase: Early Phase 1
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
A Phase 2, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of 2 mg and 4 mg SUVN-G3031 Compared to Placebo in Patients With Narcolepsy With and Without Cataplexy
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Drug
Study Drug: SUVN-G3031
Study Phase: Phase 2
A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of VIB9600 by Intravenous Infusion or Subcutaneous Injection in Healthy Subjects
A Phase 1 Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of VIB9600 by Intravenous Infusion or Subcutaneous Injection in Healthy Subjects
Enrollment Status: Terminated
Publish Date: December 13, 2024
Intervention Type: Drug, Biological
Study Phase: Phase 1
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
A Randomized, Double-Blind, Placebo-Controlled, Multiple Rising Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TAK-994 in Patients With Narcolepsy With or Without Cataplexy (Narcolepsy Type 1 or Narcolepsy Type 2)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drug: TAK-994
Study Phase: Phase 2
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
A Dose-Blind Extension Study With Double-blind, Placebo-Controlled, Randomized Withdrawal Period to Evaluate the Safety and Explore the Pharmacokinetics and Pharmacodynamics of TAK-994 in Adults With Narcolepsy With Cataplexy (Narcolepsy Type 1)
Enrollment Status: Terminated
Publish Date: December 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: November 27, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Phase 2, Randomized, 3-Period, Placebo-Controlled Crossover Study to Evaluate the Efficacy and Safety in Obstructive Sleep Apnea of AD036 Versus Placebo or Atomoxetine
Enrollment Status: Completed
Publish Date: September 14, 2023
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
An Open-Label, 12-Month Study to Evaluate the Safety and Tolerability of STS101 (Dihydroergotamine Nasal Powder) in the Acute Treatment of Migraine
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Drug: Dihydroergotamine
Study Phase: Phase 3
View 9 Less Clinical Trials

6 Total Publications

The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
The Combination of Aroxybutynin and Atomoxetine in the Treatment of Obstructive Sleep Apnea (MARIPOSA): A Randomized Controlled Trial.
Journal: American journal of respiratory and critical care medicine
Published: October 09, 2023
Similar Doctors
Expertise in
14
conditions
Dr. Narong Simakajornboon
Sleep Medicine
Expertise in
14
conditions
Dr. Narong Simakajornboon
Sleep Medicine

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (4.8 miles away)
513-636-6771
Languages Spoken:
English
See accepted insurances

Narong Simakajornboon is a Sleep Medicine provider in Cincinnati, Ohio. Dr. Simakajornboon is highly rated in 14 conditions, according to our data. His top areas of expertise are Laryngomalacia, Central Sleep Apnea, Obstructive Sleep Apnea, Infantile Apnea, and Adenoidectomy.

Stacey Ishman
Expertise in
12
conditions
Dr. Stacey Ishman
Sleep Medicine
Expertise in
12
conditions
Dr. Stacey Ishman
Sleep Medicine

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (4.8 miles away)
513-636-4355
Languages Spoken:
English
See accepted insurances

Stacey Ishman is a Sleep Medicine provider in Cincinnati, Ohio. Dr. Ishman is highly rated in 12 conditions, according to our data. Her top areas of expertise are Obstructive Sleep Apnea, Laryngomalacia, Mastoiditis, Adenoidectomy, and Glossectomy.

Expertise in
25
conditions
Dr. Thomas Dye
Sleep Medicine
Expertise in
25
conditions
Dr. Thomas Dye
Sleep Medicine

Cincinnati Children's Hospital Medical Center

3333 Burnet Ave, 
Cincinnati, OH 
 (4.8 miles away)
513-636-4222
Languages Spoken:
English
See accepted insurances

Thomas Dye is a Sleep Medicine provider in Cincinnati, Ohio. Dr. Dye is highly rated in 25 conditions, according to our data. His top areas of expertise are Periodic Limb Movement Disorder, Narcolepsy, Restless Legs Syndrome, Excessive Daytime Sleepiness, and Adenoidectomy.

Frequently Asked Questions about Dr. James Maynard

How do I make an appointment with Dr. James Maynard?

You can book an appointment with Dr. James Maynard by calling their office at 859-640-6548. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. James Maynard a top-rated expert for Familial Hemiplegic Migraine?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. James Maynard is classified as an Advanced expert for Familial Hemiplegic Migraine, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. James Maynard specialize in?

While Dr. James Maynard is a Sleep Medicine, they have specific expertise in Familial Hemiplegic Migraine, Migraine with Brainstem Aura, and Obstructive Sleep Apnea. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Sleep Medicine.

Does Dr. James Maynard participate in research or clinical trials?

Yes. Dr. James Maynard has published 6 articles and abstracts on conditions like Familial Hemiplegic Migraine. You can view a list of Dr. James Maynard's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Maynard's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile